非小细胞肺癌中BRCA1表达与铂类耐药及预后关系  

Non Small Cell Lung Cancer in BRCA1 Expression and Platinum Resistance and its Relationship

作　　者：邓双年[1] 郑玲[2] 

机构地区：[1]成都大学附属医院肿瘤科,成都610081 [2]成都大学附属医院,成都610081

出　　处：《四川解剖学杂志》2012年第2期51-54,共4页Sichuan Journal of Anatomy

摘　　要：肺癌是世界上发病率和死亡率最高的肿瘤,我国是肺癌的高发国家。铂是目前最常用的非小细胞肺癌(NSCLC)肿瘤化疗药物。铂类药物的耐药是多种机制共同作用的结果。人乳腺癌易感基因1(BRCA1)是一种抑癌基因,有细胞损伤修复、细胞蛋白调控、细胞凋亡等多重作用。BRCA1是非小细胞肺癌患者铂类药物敏感性的最佳敏感指标之一。BRCA1与肿瘤分期联合检测可作为预测患者生存期。Lung cancer is the morbidity and mortality in the world＇s highest tumor,China is a country of high incidence of lung cancer.Platinum is the most commonly drug used in non-small cell lung cancer（non-small-cell lung cancer,NSCLC） chemotherapy.Platinum drug resistance is the result of a variety of mechanisms together.Cancer susceptibility,breast cancer susceptibility gene1（BIRADS gene1,BRCA1） is a tumor suppressor gene,and has multiple roles,such as cell damage repair,cell protein regulation,apoptosis.BRCA1 is one of platinum sensitive indicators of drug sensitivity for non-small cell lung cancer patients.The joint detection of BRCA1 and tumor stage may be as a predictor of patient survival.

关 键 词：非小细胞肺癌 人乳腺癌易感基因1 铂 耐药 

分 类 号：R734.2[医药卫生—肿瘤]